DAX23.970 -1,0%ESt505.338 -0,3%Top 10 Crypto16,23 +2,0%Dow44.838 -0,1%Nas21.179 +0,3%Bitcoin101.491 -0,1%Euro1,1593 -1,3%Öl70,39 +2,9%Gold3.317 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Volkswagen (VW) vz. 766403 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 Bayer BAY001 Deutsche Bank 514000 BASF BASF11 Tesla A1CX3T DroneShield A2DMAA Porsche PAG911 Novo Nordisk A3EU6F HENSOLDT HAG000 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-EU-Zolldeal im Blick: DAX schließt unter 24.000 Punkten -- US-Börsen letztlich uneins -- NVIDIA-Aktie: Huawei stellt Konkurrenzsystem vor -- TUI, Amazon, Clara Tech, D-Wave, PUMA, Intel im Fokus
Top News
NVIDIA-Aktie trotzt Unsicherheit: Huawei stellt Konkurrenzsystem CloudMatrix 384 vor NVIDIA-Aktie trotzt Unsicherheit: Huawei stellt Konkurrenzsystem CloudMatrix 384 vor
D-Wave Quantum-Aktie: 29% Kursexplosion in einem Monat - Es bleibt weiter spannend D-Wave Quantum-Aktie: 29% Kursexplosion in einem Monat - Es bleibt weiter spannend
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
25 € Neukundenbonus + 1 Aktie gratis. Hol Dir jetzt Dein finanzen.net ZERO-Depot!

Neurocrine Biosciences Aktie

Handeln
Aktien-Sparplan anlegen
115,55 EUR +3,00 EUR +2,67 %
BMN
133,73 USD +1,72 USD +1,30 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.11,15 Mrd. EUR

KGV41,47Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
PR NewswireNeurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Co...
PR NewswireNeurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Wer­bungNeurocrine Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireNeurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
PR NewswireNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Diseas...
PR NewswireNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dysk...
PR NewswireNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
PR NewswireNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive ...
PR NewswireNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
PR NewswireNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
PR NewswireNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY...
PR NewswireNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improv...
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in May
PR NewswireNeurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
PR NewswireNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
PR NewswireNeurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of C...
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
PR NewswireNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
PR NewswireNeurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
PR NewswireNeurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements i...
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in March
PR NewswireNeurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
PR NewswireNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
PR NewswireNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
PR NewswireAndrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
PR NewswireNeurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
PR NewswireNeurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
PR NewswireNeurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.